Dual-Targeting BBB Shuttle-Amyloid Antibodies
🧪 Overview
Engineer bispecific antibodies that simultaneously target amyloid-β and brain endothelial transferrin receptors (TfR). The TfR-binding domain would facilitate receptor-mediated transcytosis across the BBB, while the amyloid-binding domain would clear plaques once in the brain parenchyma.
Debate provenance: derived from debate `sess_sda-2026-04-01-gap-008` on question: Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.. Consensus signal: domain_expert, skeptic, synthesizer, theorist discussed the mechanism terms APP, Antibodies, BBB, Dual-Targeting, Shuttle-Amyloid, TFRC. Novelty signal: skeptic-discussed-with-qualified-concession.
🧬 Mechanism
Auto-built from this analysis's top knowledge-graph edges.
graph TD
FCGRT["FCGRT"] -->|encodes| FcRn_receptor["FcRn_receptor"]
FcRn_receptor_1["FcRn_receptor"] -->|mediates| antibody_transcytosis["antibody_transcytosis"]
antibody_transcytosis_2["antibody_transcytosis"] -->|treats| Alzheimer_disease["Alzheimer_disease"]
TFR1["TFR1"] -->|encodes| transferrin_receptor["transferrin_receptor"]
transferrin_receptor_3["transferrin_receptor"] -->|facilitates| receptor_mediated_transcy["receptor_mediated_transcytosis"]
LRP1["LRP1"] -->|encodes| LRP1_protein["LRP1_protein"]
LRP1_protein_4["LRP1_protein"] -->|mediates| apoE_transport["apoE_transport"]
MTNR1A["MTNR1A"] -->|encodes| melatonin_receptor["melatonin_receptor"]
melatonin_receptor_5["melatonin_receptor"] -->|controls| circadian_regulation["circadian_regulation"]
circadian_regulation_6["circadian_regulation"] -->|modulates| BBB_permeability["BBB_permeability"]
APOE["APOE"] -->|encodes| apolipoprotein_E["apolipoprotein_E"]
apolipoprotein_E_7["apolipoprotein_E"] -->|regulates| amyloid_clearance["amyloid_clearance"]
style FCGRT fill:#ce93d8,stroke:#333,color:#000
style FcRn_receptor fill:#4fc3f7,stroke:#333,color:#000
style FcRn_receptor_1 fill:#4fc3f7,stroke:#333,color:#000
style antibody_transcytosis fill:#81c784,stroke:#333,color:#000
style antibody_transcytosis_2 fill:#81c784,stroke:#333,color:#000
style Alzheimer_disease fill:#ef5350,stroke:#333,color:#000
style TFR1 fill:#ce93d8,stroke:#333,color:#000
style transferrin_receptor fill:#4fc3f7,stroke:#333,color:#000
style transferrin_receptor_3 fill:#4fc3f7,stroke:#333,color:#000
style receptor_mediated_transcy fill:#81c784,stroke:#333,color:#000
style LRP1 fill:#ce93d8,stroke:#333,color:#000
style LRP1_protein fill:#4fc3f7,stroke:#333,color:#000
style LRP1_protein_4 fill:#4fc3f7,stroke:#333,color:#000
style apoE_transport fill:#81c784,stroke:#333,color:#000
style MTNR1A fill:#ce93d8,stroke:#333,color:#000
style melatonin_receptor fill:#4fc3f7,stroke:#333,color:#000
style melatonin_receptor_5 fill:#4fc3f7,stroke:#333,color:#000
style circadian_regulation fill:#81c784,stroke:#333,color:#000
style circadian_regulation_6 fill:#81c784,stroke:#333,color:#000
style BBB_permeability fill:#4fc3f7,stroke:#333,color:#000
style APOE fill:#ce93d8,stroke:#333,color:#000
style apolipoprotein_E fill:#4fc3f7,stroke:#333,color:#000
style apolipoprotein_E_7 fill:#4fc3f7,stroke:#333,color:#000
style amyloid_clearance fill:#81c784,stroke:#333,color:#000⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — TFRC
No curated PDB or AlphaFold mapping for TFRC yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for TFRC (transferrin receptor), APP.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_round_mining
| source | v1_phase_c_backfill |
| origin_type | debate_round_mining |
| _schema_version | 1 |